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During the past 30 years, a mounting body of evidence has demonstrated that depression is a
significant comorbid condition for patients with type 1 or type 2 diabetes. Patients with
diabetes have been found to be two times more likely to experience depressive symptoms
than their peers without diabetes.1 Rates of elevated depressive symptoms have been found
to range from 21 to 27% in type 1 diabetes and type 2 diabetes, respectively, with lower
rates (11.4%) observed in studies using psychiatric interviews in which symptoms
attributable to other causes can be evaluated.1 In addition to higher depression rates among
those already diagnosed with diabetes, multiple prospective studies have documented that a
lifetime history of depression increases the risk of developing type 2 diabetes later in the life
cycle.2–5
Impact of Depression and Diabetes
Depressive symptoms have been shown to be associated with worsened blood glucose
levels6 and diabetes complications7 such as coronary heart disease.8 There is increasing
evidence that significant additional functional, fiscal, and psychological costs are associated
with depression in patients with diabetes.9–12 Several studies have documented decreased
adherence to diet, exercise, and medication regimens associated with depression among
adults with diabetes.9–11 Medical costs associated with moderate to severe levels of
depression have also been found to be 51–86% higher than among patients reporting low
levels of depression.11 Patients with diabetes and depression have been found to have 4.5
times higher medical expenditures than patients with diabetes alone. Patients with comorbid
depression also have higher ambulatory care use and fill more prescriptions.12
Comorbid depression has also been shown to have a significant impact on functional
disability. Data from the National Health Interview Study have shown that individuals with
diabetes and comorbid depression are 7.15 times more likely to experience functional
disability (i.e., impairment in work or social activities) compared to peers with either
condition alone.13 Simon et al.14 found that > 50% of patients diagnosed with both
conditions in a health maintenance organization population reported unemployment.
Finally, comorbid depression and diabetes have been found to increase the risk of early
mortality 2.3 times compared to nondepressed patients with diabetes.15 Zhang et al.16
reported a 54% increased risk of early mortality among patients reporting elevated
depression scores. As Lin et al.17 have recently documented, causes of mortality in this
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vulnerable population extend beyond cardiovascular disease to the full range of diseases and
disorders.
Depression Treatment for People With Diabetes
Despite the significant costs of comorbid depression and diabetes, traditional treatment
approaches such as psychotherapy and antidepressant medications have been found to be
efficacious in treating depression in the short term. Lustman et al.18 conducted the
benchmark randomized, controlled trial for cognitive behavioral therapy (CBT) in patients
with comorbid depression and diabetes. In this study, 70.8% of patients randomized to the
CBT treatment compared to 22.2% of patients in the control group were in depression
remission at post-treatment assessment. At 6-month follow-up assessments, depression
remission was evident in 66.6% of patients in the CBT group compared to 29.6% in the
control group. Treatment responsiveness appeared to be associated with severity of
depression and A1C at baseline.18,19 Improvements in glycemic control were observed
among patients receiving CBT 6 months after completion of treatment.
Problem-solving therapy as an integrated treatment within the primary care setting has also
been shown to be efficacious.20 Participants in the Pathways study who were randomized to
a stepped-care problem-solving therapy intervention reported higher levels of treatment
exposure and satisfaction with care and improved depression outcomes compared to patients
in the usual-care group. In this study, improvements in glycemic control were not observed
immediately after care or at 6- or 12-month follow-up assessments.20
Randomized, controlled trials have demonstrated the efficacy of antidepressant medications
on depression outcomes in type 1 and type 2 diabetic patients. In a randomized trial,
nortryptiline was found to improve depression compared to placebo with hyperglycemic
effects observed at post-treatment.21 A variety of studies have examined the efficacy of
selective serotonin reuptake inhibitor medications, including fluoxetine, sertraline,
paroxetine, and buproprion.22–26 All have been shown to be effective in reducing depressive
symptoms with either hypoglycemic (e.g., fluoxetine, buproprion) or euglycemic
(paroxetine) effects.
Challenges to Treatment Outcomes: Access to Care and Depression
Relapse
Although treatment has been shown to be efficacious, challenges remain that contribute to
health outcomes for patients with diabetes and depression. One challenge is access to mental
health treatment, which includes significant delays in reaching administrative staff to discuss
and schedule appointments in urban areas27 and limited numbers of providers in rural
areas.28 Even when traditional treatment options are implemented that make use of the
primary care medical system in underserved rural areas, barriers to adoption and
implementation, including patient refusal of treatment, limited provider engagement, and
difficulty training staff, pose threats to building treatment capacity in rural areas.29 Among
ethnic and racial groups, disparities in access and unique cultural barriers to quality care,
including language translation, cultural understanding on the part of providers, and
availability of a limited number of providers, pose even greater challenges to seeking and
obtaining adequate mental health treatment.30
Relapse of depressive symptoms also remains a challenge for patients and providers. In a
longitudinal cohort of men and women with type 1 or type 2 diabetes, Lustman et al.31
found that 92% of individuals who had been successfully treated for major depression
experienced a relapse of one or more episodes during a 5-year follow-up period. Depressive
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symptoms also appear to be persistent over time. Studies of type 2 diabetic patients have
shown that between 70 and 77% of individuals reporting elevated depressive symptoms at a
baseline survey continued to report depressive symptoms up to 18 months later.32,33 In
contrast, epidemiological data of episode duration of major depressive disorder in the
general population has noted an average duration of 8–12 weeks.34 Additional data are
needed to further characterize the long-term pattern of depression for people with diabetes.
Addressing the Challenges: Screening and Supporting Treatment
Taken together, these challenges highlight the need to work effectively and creatively within
current health care settings to identify depression and support its treatment. The existence of
significant discrepancies between observed rates of clinically significant depressive
symptoms and diagnosis among primary care providers35 points to the need for thoughtful
and efficient screening of patients so that a dialogue about treatment may begin. In addition,
studies documenting high rates of depression relapse suggest the need for routine monitoring
and management of symptoms beyond depression treatment to effectively treat recurrent
depression symptoms.
A variety of tools are available to screen patients for the presence and severity of depression,
including self-report questionnaires and brief clinical interview questions. Tools such as the
Patient Health Questionnaire-936 and the Beck Depression Inventory37 may be incorporated
into the beginning of a clinic visit or used interactively with a health care provider or staff
member. Brief interpersonal questions such as those found on the two-item version of the
Patient Health Questionnaire38 can be used by providers to query patients about changes in
mood during the past 2 weeks or since the last visit.
Such screening should be conducted in conjunction with staff-assisted diagnosis, treatment,
and follow-up care as recommended by the U.S. Preventive Services Task Force.39 For
example, patient questionnaires should be reviewed before completion of the patient visit so
that responses indicating severe levels of depressive symptoms or indications of suicidal
intent or plan can be further assessed and addressed promptly and directly with the patient.
Provider practices that engage in screening should train staff in notification and referral
protocols so that patients’ needs for immediate care can be met.
Once screening has taken place, providers have an opportunity to discuss with their patients
the relationship between diabetes and depression and to review treatment options. This
dialogue, however brief, serves multiple purposes: to validate the importance of presenting
mood symptoms to the medical encounter, educate patients about the impact of depression
on diabetes self-management and outcomes, provide an opportunity for patients to express
concerns about depression treatment and feelings of stigma, and empower patients to report
changes in mood symptoms during future visits to facilitate follow-up assessment and
treatment.
Finally, barriers to depression treatment can be addressed, in part, through integrated
approaches to diabetes health care. The Pathways study20 has provided one model for
integrated care in which trained nursing staff provided problem-solving therapy to depressed
patients within a primary care setting. Primary care psychology has emerged as a subfield
that provides a variety of models of coordinated patient care for mental health and medical
issues. Models range from curbside consultation to fully integrated care in which
psychologists work side by side with medical providers to provide consultations and
treatment on a part- or full-time basis.40 Providers and health care systems can work
creatively to lower barriers to care within the organizational, historical, and functional
context of their practices.
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Summary
During the past 30 years, findings from studies of the prevalence and impact of depression
in people with diabetes have documented significant adverse effects of depression on
morbidity and mortality when both conditions are present. Fortunately, conventional
treatments for depression such as anti-depressant medications and cognitive behavioral
therapy have been shown to be effective in treating depression in people with diabetes.
Challenges remain for providers and patients to be more aware of depressive symptoms. The
inclusion of established depression screening protocols in diabetes clinical management
pathways would increase provider awareness, screening, and psychological referral. These
steps could result in earlier detection and initiation of depression treatment. These steps can
also facilitate open dialogue between patients and their providers to overcome the attitudinal
and logistical barriers to depression treatment and encourage careful monitoring of patients
beyond treatment to reduce the potential impact of depression relapse. Further research is
needed to continue to develop effective and accessible treatment options for patients to
manage persistent mood symptoms.
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